Literature DB >> 10968493

Defaulting from tuberculosis treatment in The Netherlands: rates, risk factors and trend in the period 1993-1997.

M W Borgdorff1, J Veen, N A Kalisvaart, J F Broekmans, N J Nagelkerke.   

Abstract

The aim of this study was to assess the rate of defaulting from treatment among tuberculosis patients diagnosed in the Netherlands in the period 1993-1997, whether risk groups for defaulting can be identified at the start of treatment and the trend of defaulting over time. The Netherlands Tuberculosis Register provided data on all patients diagnosed in the Netherlands during the period 1993-1997. Defaulting probabilities were determined using Kaplan-Meier survival analysis and risk factors were identified with Cox's proportional hazard analysis. Of 7,529 patients with reported treatment outcome, 718 (10%) defaulted or left the country within 1 yr after starting treatment. Defaulting probabilities were 9% (95% confidence interval (CI) 8-10%) among 5,256 patients in low-risk groups, 17% (95% CI 14-19%) among 1,437 asylum seekers and 29% (95% CI 24-34%) among 836 patients in other high-risk groups (other recent immigrants, illegal immigrants, the homeless, prisoners and nationals from Eastern Europe). Defaulting probabilities decreased over time from 12% in 1993 to 7% in 1997. Risk groups for defaulting can be recognized at the start of treatment. The decreasing defaulting probabilities were probably due in part to shortening treatment from 9 to 6 months and improved follow-up of asylum seekers. However, additional measures are needed to reduce defaulting among the homeless, recent immigrants, illegal immigrants and prisoners.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10968493     DOI: 10.1034/j.1399-3003.2000.16b05.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  Active tuberculosis among homeless persons, Toronto, Ontario, Canada, 1998-2007.

Authors:  Kamran Khan; Elizabeth Rea; Cameron McDermaid; Rebecca Stuart; Catharine Chambers; Jun Wang; Angie Chan; Michael Gardam; Frances Jamieson; Jae Yang; Stephen W Hwang
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

2.  Risk factors associated with loss to follow-up from tuberculosis treatment in Tajikistan: a case-control study.

Authors:  Jessica Wohlleben; Mavluda Makhmudova; Firuza Saidova; Shahnoza Azamova; Christina Mergenthaler; Suzanne Verver
Journal:  BMC Infect Dis       Date:  2017-08-04       Impact factor: 3.090

3.  Clinical presentation, demographics and outcome of tuberculosis (TB) in a low incidence area: a 4-year study in Geneva, Switzerland.

Authors:  Omar Kherad; François R Herrmann; Jean-Pierre Zellweger; Thierry Rochat; Jean-Paul Janssens
Journal:  BMC Infect Dis       Date:  2009-12-31       Impact factor: 3.090

Review 4.  Tuberculosis treatment outcome monitoring in European Union countries: systematic review.

Authors:  Rob van Hest; Csaba Ködmön; Suzanne Verver; Connie G M Erkens; Masja Straetemans; Davide Manissero; Gerard de Vries
Journal:  Eur Respir J       Date:  2012-07-12       Impact factor: 16.671

5.  Treatment outcome of new smear positive pulmonary tuberculosis patients in Penang, Malaysia.

Authors:  Muhammad Atif; Syed Azhar Syed Sulaiman; Asrul Akmal Shafie; Irfhan Ali; Muhammad Asif; Zaheer-Ud-Din Babar
Journal:  BMC Infect Dis       Date:  2014-07-19       Impact factor: 3.090

6.  The impact of being homeless on the unsuccessful outcome of treatment of pulmonary TB in São Paulo State, Brazil.

Authors:  Otavio T Ranzani; Carlos R R Carvalho; Eliseu A Waldman; Laura C Rodrigues
Journal:  BMC Med       Date:  2016-03-23       Impact factor: 8.775

7.  A combination of quantitative and qualitative methods in investigating risk factors for lost to follow-up for tuberculosis treatment in Japan - Are physicians and nurses at a particular risk?

Authors:  Lisa Kawatsu; Kazuhiro Uchimura; Akihiro Ohkado; Seiya Kato
Journal:  PLoS One       Date:  2018-06-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.